{"filings":[{"id":126503,"accession_number":"0001493152-25-025156","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AccuStem submits Medicare coverage application for MSC lung cancer test; enters Novitas review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted local coverage determination to Novitas Solutions for MSC test reimbursement.","Novitas confirmed application complete and valid; now in review queue for JL region (DC, DE, MD, NJ, PA).","MSC test analyzes 24 circulating microRNAs in plasma to classify lung nodule risk.","If approved, could reduce unnecessary biopsies for benign nodules and prioritize high-risk patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179539,"accession_number":"0001493152-25-000089","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K/A","filed_at":"2025-01-02T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"AccuStem Sciences amends 8-K to correct name of independent accounting firm","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to Dec 30, 2024 8-K solely to revise the name of the independent registered public accounting firm.","Mercurius & Associates LLP (PCAOB No. 3223) was appointed on June 17, 2024.","No other modifications to the initial 8-K disclosure.","No prior consultations or disagreements with Mercurius before appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196266,"accession_number":"0001493152-24-052550","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"AccuStem Sciences appoints Mercurius LLP as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mercurius LLP appointed as AccuStem Sciences' independent registered public accounting firm effective June 17, 2024.","No prior consultations with Mercurius regarding accounting principles or reportable events occurred during fiscal years 2022-2023.","8-K signed December 30, 2024, approximately six months after the appointment date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231553,"accession_number":"0001493152-24-014171","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Auditor Mazars USA LLP resigns; company seeks replacement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mazars to resign effective with Q1 2024 10-Q filing, no later than May 31, 2024.","No adverse opinions or disagreements for fiscal years 2022 and 2023.","Company disclosed material weakness in internal control over financial reporting due to lack of accounting resources.","Company is in process of retaining a new independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304365,"accession_number":"0001493152-23-020727","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"COO Jeff Fensterer resigns effective June 16; will become consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Fensterer resigned as COO for personal reasons, effective June 16, 2023.","Fensterer will transition to a consulting role with the company.","No successor appointed at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304364,"accession_number":"0001493152-23-020328","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AccuStem Sciences furnishes corporate presentation for investor meetings","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company intends to conduct meetings with third parties using a corporate slide presentation.","Presentation attached as Exhibit 99.1 but content not provided in the filing text.","No financial results, guidance, or material events disclosed in this 8-K.","Filing is a routine Regulation FD disclosure; no new substantive information for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341956,"accession_number":"0001493152-22-032628","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AccuStem Sciences appoints Sean McDonald as independent director; board now five members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sean McDonald appointed to AccuStem board effective Nov. 14, 2022; board expanded from four to five members.","McDonald currently CEO of Ocugenix, a therapeutics company focusing on ocular diseases.","He previously scaled Automated Healthcare (acquired by McKesson) and served as CEO of Precision Therapeutics.","McDonald was a director at Respironics before its $5.1B acquisition by Philips."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341955,"accession_number":"0001493152-22-028454","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2022-10-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AccuStem Sciences stockholders approve reverse stock split authorization at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Wendy Blosser, Gabriele Cerrone, Willy Simon, John Brancaccio with >7M votes each.","Ratified Mazars USA LLP as independent auditor for fiscal year ending Dec 31, 2022.","Approved amendment to certificate of incorporation to effect reverse stock split (1:2 to 1:15) before Oct 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377543,"accession_number":"0001493152-22-017353","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kunwar Shalubhai resigns from AccuStem board effective June 20, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kunwar Shalubhai resigned as member of the Board, effective immediately on June 20, 2022.","Resignation not due to any disagreement with the Company's operations, policies, or practices.","No replacement named in the filing; board size and composition affected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377542,"accession_number":"0001493152-22-009142","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2022-04-05T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"AccuStem Sciences sells 1.34M shares to Tiziana Life Sciences at $2.00/sh, raising $2.68M; CEO also joins board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tiziana Life Sciences purchased 1,337,970 shares of AccuStem common stock at $2.00 per share for gross proceeds of $2,675,940.","Sale was pursuant to a Supplemental Demerger Agreement from Oct 2021, requiring Tiziana to buy £2M shares at listing.","Shares are unregistered and offered under Regulation S exemption.","CEO Wendy Blosser appointed to the Board of Directors, effective March 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395921,"accession_number":"0001493152-22-006524","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AccuStem Sciences appoints Wendy Blosser as CEO with $425k salary and options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wendy Blosser appointed CEO effective March 4, 2022.","Base salary of $425,000 per year; eligible for annual bonus of 45% of base, with $47,813 guaranteed in Q1 2022.","Initial stock option award of 490,000 shares at $2.13 exercise price, subject to board approval.","50% of options vest over 4 years; 25% upon $30M equity fundraise; 25% upon CLIA lab launch by Q4 2023.","Employment is at-will; offer contingent on background check and restrictive covenant agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414820,"accession_number":"0001493152-21-030432","cik":1850767,"company_name":"Accustem Sciences Inc.","ticker":"ACUT","form_type":"8-K","filed_at":"2021-12-03T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","5.03","5.05","8.01","9.01"],"status":"ready","headline":"Accustem Sciences redomiciled from UK to Delaware via court-approved scheme of arrangement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redomiciled from UK to Delaware via court-approved scheme of arrangement effective Dec 1, 2021.","Share exchange: 20 old ordinary shares for 1 new share; 10 ADS for 1 new share; 9,999,132 new shares issued.","New Accustem authorized 150M common shares ($0.001 par) and 10M preferred; 2021 Plan reserves 2M shares.","New options for 1,069,244 shares, exercise prices $0.42-$1.06, expiring August/November 2031.","Adopted new bylaws, indemnification agreements, and code of business conduct."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4138608.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}